Cara Therapeutics Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 55

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Cara Therapeutics General Information

Description

Developer of a biotechnology research platform designed to discover and develop immunotherapy treatments for cancers that resist existing immune-based therapies. The company offers epigenetic drug discovery, preclinical research, tumor microenvironment reprogramming, immunotherapy combination development, and therapeutic validation capabilities, enabling pharmaceutical companies and research institutions to advance cancer treatment development and improve the effectiveness of immunotherapy approaches.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 4 Stamford Plaza
  • 107 Elm Street, 9th Floor
  • Stamford, CT 06902
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 4 Stamford Plaza
  • 107 Elm Street, 9th Floor
  • Stamford, CT 06902
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cara Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Merger/Acquisition 15-Apr-2025 Completed Generating Revenue
14. PIPE 15-Oct-2020 Completed Generating Revenue
13. Secondary Transaction - Open Market Completed Generating Revenue
12. PIPE 20-Aug-2019 Completed Generating Revenue
11. 2PO 29-Jul-2019 Completed Generating Revenue
10. Secondary Transaction - Open Market 18-Apr-2016 Completed Generating Revenue
9. Secondary Transaction - Open Market 17-Apr-2015 Completed Generating Revenue
8. IPO 31-Jan-2014 Completed Generating Revenue
7. Later Stage VC $8M $68.4M Completed Generating Revenue
6. Later Stage VC (Series D) 31-Jan-2013 $2.9M $60.4M Completed Generating Revenue
To view Cara Therapeutics’s complete valuation and funding history, request access »

Cara Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Junior A
Junior Preferred
Series D
Series C
Series B 2,254,417 $0.001000 $2 $2 1x $1.84 6.85%
Series A 1,677,118 $0.001000 $1 $1 1x $1 4.69%
To view Cara Therapeutics’s complete cap table history, request access »

Cara Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotechnology research platform designed to discover and develop immunotherapy treatments for cancers tha
Drug Discovery
Stamford, CT
55 As of 2023

South San Francisco, CA
 

Dublin, Ireland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cara Therapeutics Competitors (38)

One of Cara Therapeutics’s 38 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Prothena Corporation Dublin, Ireland
Cerecin Venture Capital-Backed Broomfield, CO
Baliopharm Venture Capital-Backed Basel, Switzerland
Elevar Therapeutics Formerly VC-backed Fort Lee, NJ
You’re viewing 5 of 38 competitors. Get the full list »

Cara Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cara Therapeutics Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alta Partners Venture Capital Minority
Amzak Health Venture Capital Minority
Ascent Biomedical Ventures Venture Capital Minority
CSL Vifor Corporation Minority
Connecticut Innovations Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Cara Therapeutics Acquisitions (1)

Cara Therapeutics’s most recent deal was a Reverse Merger with Tvardi Therapeutics. The deal was made on 15-Apr-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tvardi Therapeutics 15-Apr-2025 Reverse Merger Drug Discovery
To view Cara Therapeutics’s complete acquisitions history, request access »

Cara Therapeutics ESG

Risk Overview

Risk Rating

Updated April, 30, 2024

28.97 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,744

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Biotechnology

Subindustry

of 369

Rank

Percentile

To view Cara Therapeutics’s complete esg history, request access »

Cara Therapeutics FAQs

  • When was Cara Therapeutics founded?

    Cara Therapeutics was founded in 2004.

  • Where is Cara Therapeutics headquartered?

    Cara Therapeutics is headquartered in Stamford, CT.

  • What is the size of Cara Therapeutics?

    Cara Therapeutics has 55 total employees.

  • What industry is Cara Therapeutics in?

    Cara Therapeutics’s primary industry is Drug Discovery.

  • Is Cara Therapeutics a private or public company?

    Cara Therapeutics is a Private company.

  • What is Cara Therapeutics’s current revenue?

    The current revenue for Cara Therapeutics is .

  • How much funding has Cara Therapeutics raised over time?

    Cara Therapeutics has raised $319M.

  • Who are Cara Therapeutics’s investors?

    Alta Partners, Amzak Health, Ascent Biomedical Ventures, CSL Vifor, and Connecticut Innovations are 5 of 14 investors who have invested in Cara Therapeutics.

  • Who are Cara Therapeutics’s competitors?

    CytomX Therapeutics, Prothena, Cerecin, Baliopharm, and Elevar Therapeutics are some of the 38 competitors of Cara Therapeutics.

  • When was Cara Therapeutics acquired?

    Cara Therapeutics was acquired on 15-Apr-2025.

  • Who acquired Cara Therapeutics?

    Cara Therapeutics was acquired by Tvardi Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process